文献速递头颈部肿瘤放疗

西妥昔单抗联合常规放疗能否改善诱导化疗有效的局部晚期喉癌患者的器官保留?

Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-17

这项2期、开放标签、多中心研究纳入适合全喉切除术的III和IVA期喉癌患者,先接受3周期TPF诱导化疗,有效者再接受西妥昔单抗联合常规放疗。主要终点3年功能性喉生存率为70%(95%CI 60%-79%),高于预设的59%临界值,毒性可接受,支持开展3期试验。

要点

  • 诱导化疗有效者接受西妥昔单抗联合放疗,3年功能性喉生存率达70%。
  • 3年无喉切除术生存率为72%,总生存率为78%。
  • 毒性总体符合预期,仅1例治疗相关死亡(放疗期间局部出血)。

核心结论

  • 按本方案,功能性喉生存率明显高于59%的临界值,毒性水平可接受。
  • 对TPF诱导化疗有效的III和IVA期喉癌患者,放疗联合西妥昔单抗可能改善功能性喉保留。
  • 研究者认为有必要开展3期临床试验。

研究设计与样本

  • 这是一项2期、开放标签、多中心研究,纳入III和IVA期喉癌且适合全喉切除术的患者。
  • 患者接受3周期TPF(多西他赛、顺铂和5-氟尿嘧啶)诱导化疗,有效者接受西妥昔单抗联合常规放疗。
  • 主要终点为3年功能性喉生存率,研究阳性临界值为SFL>59%。
  • 共93例患者开始TPF诱导化疗。

主要发现

  • 诱导化疗对喉靶病灶的疗效:37例(40%)完全缓解,38例(41%)部分缓解,8例(9%)稳定,2例(2%)进展,8例(9%)未评估(2例死亡、5例不良事件、1例失访)。
  • 中位随访53.7个月,3年功能性喉生存率为70%(95%CI 60%-79%)。
  • 3年无喉切除术生存率为72%(95%CI 61%-81%),总生存率为78%(95%CI 63%-82%)。
  • 诱导化疗和生物放疗期间急性毒性符合预期,生物放疗期间仅1例毒性相关死亡(局部出血)。

关键数值与推荐

  • 研究阳性临界值为3年功能性喉生存率>59%。
  • 患者接受3周期TPF诱导化疗,有效者接受西妥昔单抗联合常规放疗。
  • 生物放疗后残留淋巴结病变者计划在生物放疗后2个月行颈淋巴结清扫。
  • 诱导化疗无效者接受全喉切除术加颈淋巴结清扫和放疗。

临床怎么用

  • 对适合全喉切除术的III和IVA期喉癌患者,可考虑TPF诱导化疗后以西妥昔单抗联合常规放疗作为功能性喉保留策略。
  • 诱导化疗无效者应按方案接受全喉切除术加颈淋巴结清扫和放疗。
  • 生物放疗后残留淋巴结病变者应在生物放疗后2个月评估并考虑颈淋巴结清扫。

局限性

  • 这是一项2期、开放标签、单臂研究,未设随机对照。
  • 部分患者未评估诱导化疗疗效(8例,9%),其中2例死亡、5例不良事件、1例失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of induction chemotherapy (IC) followed by bioradiotherapy (BRT) to achieve functional larynx preservation in the setting of locally advanced head and neck tumors. METHODS AND MATERIALS: This was a phase 2, open-label, multicenter study of patients with stage III and IVA laryngeal carcinoma who were candidates for total laryngectomy. The primary endpoint was the rate of survival with functional larynx (SFL) at 3 years, with a critical value to consider the study positive of SFL >59%. Patients received 3 cycles of IC with TPF (docetaxel, cisplatin, and 5-fluorouracil), and those who responded received conventional BRT with cetuximab. In patients with residual nodal disease after BRT, neck dissection was planned 2 months after BRT. Patients who did not respond to IC underwent total laryngectomy plus neck dissection and radiation therapy. RESULTS: A total of 93 patients started TPF. Responses to IC on larynx target lesion were as follows: 37 patients (40%) showed a complete response; 38 patients (41%) showed a partial response; 8 patients (9%) showed stabilization; 2 patients (2%) showed progressive disease, and 8 patients (9%) were not evaluated (2 deaths, 5 adverse events, and 1 lost to follow-up). Seventy-three patients (78%) received BRT: 72 as per protocol, but 1 with only stable disease. Median follow-up was 53.7 months. Three-year actuarial rates were as follows: SFL: 70% (95% confidence interval [CI] 60%-79%); laryngectomy-free survival: 72% (95% CI 61%-81%); overall survival: 78% (95% CI: 63%-82%). The acute toxicity observed during both IC and BRT was as expected, with only 1 toxicity-related death (local bleeding) during BRT. CONCLUSIONS: According to this protocol, the SFL rate was clearly higher than the critical value, with acceptable levels of toxicity. The use of cetuximab added to radiation therapy in patients with stage III and IVA laryngeal cancer who respond to TPF could improve functional larynx preservation. A phase 3 trial is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mesía R, Garcia-Saenz JA, Lozano A, et al. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. Int J Radiat Oncol Biol Phys. 2016. PMID: 28011050. doi:10.1016/j.ijrobp.2016.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。